Dave Johnson

Dave Johnson has 25+ years of experience in the biopharmaceutical industry. He is currently CEO and founder of SolveTx, a mAb based oncology therapeutics start-up. Prior to SolveTx, Dave was chairman of the precision oncology-focused Lengo Therapeutics, which closed a strategic transaction with BPMC in December 2021 valued at up to $465M. Prior to Lengo, Dave was CEO of VelosBio, an oncology-focused, biopharmaceutical company that he founded in December 2017. Velos created novel monoclonal antibody-based therapeutics, rapidly moving its lead first-in-class ROR1-directed antibody-drug-conjugate VLS-101 (zilovertamab vedotin) from pre-IND through Phase 1 clinical development. Ultimately, VelosBio was acquired by Merck in December 2020 for $2.75B.